Our portfolio company ARTIDIS announces today promising data from their first prospective study conducted at the Breast Center in Basel, Switzerland. The spin-off from the Biozentrum at the University of Basel has succesfully developed the first nanomechanical biomarker for cancer diagnosis and treatment optimization.
ARTIDIS AG CLINICAL STUDY PRESS RELEASE_ULTIMATE_FINAL_fixed_mgmt_Dr Burian aloneHEMEX AG is a privately-owned Swiss investment and consulting company headquartered close to the Basel global life sciences hub, with its main focus to bring innovative drugs, medical devices and in vitro diagnostics to the market. HEMEX specializes in supporting early-stage start-ups, offering tailored solutions to accelerate the project into a successful and sustainable business. Additionally, HEMEX helps start-ups in their efforts to find non-dilutive and dilutive funding. More at https://hemex.eu/